SAN DIEGO, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)LA JOLLA INFECTIOUS DISEASE INSTITUTE, founded in 2007, is a small nonprofit in the Medical Research sector that reported $517K in total revenue in fiscal year 2022. Revenue surged 135% from the prior year, signaling strong growth momentum. Expenses of $441K left a modest 15% surplus.
THE SPECIFIC PURPOSE OF THIS CORPORATION IS FOR THE ADVANCEMENT OF SCIENCE AND FOR RESEARCH PURPOSES AS DEFINED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE, INCLUDING THE IMPROVED TREATMENT, RESEARCH DESIGN AND METHODS, AND KNOWLEDGE RELATED TO THE ALLERGIC RESPONSE, INFECTIOUS DISEASE, AND IMMUNOLOGIC PATHWAYS. WE PROVIDE EDUCATIONAL ACTIVITIES FOR SCHOOL CHILDREN, UNDERGRADUATE, GRADUATE, AND POST-DOCTORAL STUDENTS.
1 JOHNS HOPKINS: STUDIES TO EXAMINE FACTORS THAT ARE SECRETED INTO THE MOUSE BRAIN DURING EXPERIMENTAL CEREBRAL MALARIA AND THAT CONTRIBUTE TO PATHOGENESIS. 2 THE NATIONAL INSTITUTES OF HEALTH FUNDED...
1 JOHNS HOPKINS: STUDIES TO EXAMINE FACTORS THAT ARE SECRETED INTO THE MOUSE BRAIN DURING EXPERIMENTAL CEREBRAL MALARIA AND THAT CONTRIBUTE TO PATHOGENESIS. 2 THE NATIONAL INSTITUTES OF HEALTH FUNDED GRANT DETERMINES THE MECHANISMS WHEREBY PLATELETS ARE REMOVED FROM CIRCULATION BY THE LIVER DURING EXPERIMENTAL CEREBRAL MALARIA. 3. WUN-LING CHANG MD INC PROVIDES FUNDING FOR PILOT STUDIES, DEVELOPMENT OF NANOPARTICLES CONJUGATED WITH DRUGS FOR IMPROVED KILLING OF PLASMODIUM AS WELL AS POTENTIAL ADJUNCTIVE EFFECTS AGAINST EXPERIMENTAL CEREBRAL MALARIA AND DEVELOPMENT OF NEW TREATMENTS AGAINST STREPTOCOCCUS PNEUMONIAE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2022 | 2021 | Change | |
|---|---|---|---|
| Revenue | $516,793 | $219,974 | +1.3% |
| Expenses | $440,978 | $432,211 | +0.0% |
| Net Income | $75,815 | $-212,237 | -1.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| WUN-LING CHANG MD | PRESIDENT, CEO | 2.00 |
Officer
Director
|
$14,304 | $13,729 | $28,033 |
| HENRI VAN DER HEYDE PHD | CFO | 15.00 |
Officer
Director
|
$30,188 | $18,858 | $49,046 |
| GEORGES E GRAU MD PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| KENNY CHU | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| IRENE GRAMAGLIAPHD | SECRETARY | 40.00 |
Officer
Director
|
$60,791 | $20,192 | $80,983 |
| ATUL PATEL | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2023 | $516,793 | $440,978 | $26,042 | $75,815 |
| 2022 | $219,974 | $432,211 | $7,862 | $-212,237 |
| 2021 | $307,799 | $477,000 | $24,259 | $-169,201 |
| 2020 | $278,057 | $399,266 | $39,912 | $-121,209 |
| 2019 | $290,954 | $355,011 | $11,633 | $-64,057 |
| 2018 | $278,939 | $337,142 | $72,704 | $-58,203 |
Compare LA JOLLA INFECTIOUS DISEASE INSTITUTE with other nonprofits in California and across the country.